Ignite Creation Date:
2024-05-06 @ 8:19 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06334198
Status:
RECRUITING
Last Update Posted:
2024-03-28
First Post:
2024-03-20
Brief Title:
The Effect of Naldemedine on Opioid-induced Bowel Dysfunction
Sponsor:
Asbjørn Mohr Drewes
Organization:
Aalborg University Hospital
Study Overview
Official Title:
The Effect of Naldemedine on Opioid-induced Bowel Dysfunction An Investigator Initiated Randomized Double-blinded Placebo-controlled Cross-over Clinical Trial
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Opioid-induced bowel dysfunction is a frequent condition during opioid therapy for chronic pain Indeed up to 90 of people on opioid treated patients experience constipation Standard laxative treatment is often ineffective in opioid-induced constipation but peripheral acting mu-receptor antagonists PAMORAs have the potential to block the effects of opioids in the gastrointestinal tract while preserving the central analgesic effect In this study we will investigated the effects of Naldemedine in preventing the development of opioid-induced bowel dysfunction and constipation during treatment with tramadol
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-507744-36-00 | CTIS | None | None |